CD4 and cancer: Strikingly, multiparametric flow cytometry analyses revealed that TGFBI was abundantly expressed by tumor cells or monocytes, and by various lymphoid cell types-including CD4<sup>+</sup> or CD8<sup>+</sup> T cells (including tissue-resident memory T cells), B cells, and natural killer cells-in patients with cancer.